Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma
The recurrence rate was not significantly reduced in patients who underwent PCT. Hepatic impairment during treatment may indicate recurrence, and close monitoring of liver function and HBV infection is recommended.
Authors
- Yuan Cheng (ORCID: https://orcid.org/0009-0003-0378-6221)
- Weidong Jia (ORCID: https://orcid.org/0000-0002-2664-2031)
- Ming-Tong Wei
- Zi-Ling Xu
- Jianlin Lu
- Guixiang Qian
Institutions
- University of Science and Technology of China (CN)
- Anhui Provincial Hospital (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-03-24
- DOI
- https://doi.org/10.4251/wjgo.v17.i4.101371
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32